Corporate Presentation

Global Leader in Purified Cannabis Oil Leaders in Cannabis Oil Extraction Operating in High margin, high growth segment of Cannabis Investment Summary Meaningful barriers to entry (technology, expertise licensing and scale) One of the largest extraction footprints in Canada Phase I (completed) manufacturing capacity to extract over 100,000 kg of dry cannabis annually Phase II (Est. Q2 2019) capacity to extract an additional 150,000 kg dry cannabis Significant Retail Revenue Potential Meaningful inventory build Significant sales agreements Strong pipeline of new business Material revenue realization underway in fiscal 2018 set to scale rapidly in 2019 Differentiated Extraction-Only Business Model FIRST and ONLY Canadian LP under ACMPR exclusively focused on Cannabis Oil extraction A Competitive Advantage Significant wholesale transaction for Cannabis Oil with Canopy Growth Secure Supply - Bulk Purchases: wholesale purchases from 9 LP's Processing Agreements: multi-year contracts signed with 5 LP's while negotiating multiple others Licenses: March 2018: ACMPR Oil Production Licence November 2018: Health Canada Sales Licence Pending: Australia Office of Drug Control to extract and import medical cannabis Economies of scale through large volume production and automation. Purchasing power through large scale buying Exceptional Leadership & Deep Operating Expertise Senior team with deep experience in global bio-pharmaceutical, healthcare, energy, and biotechnology manufacturing Director of Quality Assurance renowned Chromatography expert with 24-years in big Pharma qualifying/validating complex quality systems, processes & equipment Manufacturing and distribution partnerships with proven, patented formulators from other global cannabis jurisdictions Built to Exceed International Quality Standards Laboratory and manufacturing facilities purpose-built to Global CGMP standards with ISO rated pharma-grade clean rooms & critical environments. Meet or exceed standards of all cannabis markets. Allows for export globally Team with experience in Six Sigma Lean Manufacturing R & D partner on extraction technology, formulation development, commercialization of products with leading, accredited teaching hospitals, college and universities International Growth Growth & Strategy Valuation Re-Rate Growth strategy to expand to Australia provides ability to service Asia Pacific markets Actively engaging in opportunities to commence importing and exporting of medical cannabis where federally permissible 25 Australian Cultivation partners providing options for significant supply inputs Australia site expected to act as an import and export hub, subject to licensing, until such time as Australian domestic-patient-demand warrants dedicated production activities, 1 hour south-east of Melbourne TSX-V: LABS Price: $1.39/share* Market Cap: $135.6M* Issued & Outstanding: 97.5M Warrants & Options: 35.5M Fully Diluted: 133M Concurrent Financing: over- subscribed by 48.6% to $22.3M Based on market close December 7, 2018 MediPharm Labs | 18

View entire presentation